Performance of CT Compared with 18F-FDG ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma
Auteur(s) :
Mokrane, F. Z. [Auteur]
Chen, A. [Auteur]
Schwartz, L. H. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Stamatoullas, A. [Auteur]
Schiano De Colella, J. M. [Auteur]
Vercellino, L. [Auteur]
Casasnovas, O. [Auteur]
Chauchet, A. [Auteur]
Delmer, A. [Auteur]
Nicolas-Virelizier, E. [Auteur]
Ghesquières, H. [Auteur]
Moles-Moreau, M. P. [Auteur]
Schmitt, A. [Auteur]
Duléry, R. [Auteur]
Bouabdallah, K. [Auteur]
Borel, C. [Auteur]
Touati, M. [Auteur]
Deau-Fischer, B. [Auteur]
Peyrade, F. [Auteur]
Seban, R. D. [Auteur]
Manson, G. [Auteur]
Houot, R. [Auteur]
Dercle, L. [Auteur]
Chen, A. [Auteur]
Schwartz, L. H. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Stamatoullas, A. [Auteur]
Schiano De Colella, J. M. [Auteur]
Vercellino, L. [Auteur]
Casasnovas, O. [Auteur]
Chauchet, A. [Auteur]
Delmer, A. [Auteur]
Nicolas-Virelizier, E. [Auteur]
Ghesquières, H. [Auteur]
Moles-Moreau, M. P. [Auteur]
Schmitt, A. [Auteur]
Duléry, R. [Auteur]
Bouabdallah, K. [Auteur]
Borel, C. [Auteur]
Touati, M. [Auteur]
Deau-Fischer, B. [Auteur]
Peyrade, F. [Auteur]
Seban, R. D. [Auteur]
Manson, G. [Auteur]
Houot, R. [Auteur]
Dercle, L. [Auteur]
Titre de la revue :
Radiology
Nom court de la revue :
Radiology
Numéro :
295
Pagination :
192056
Éditeur :
RSNA
Date de publication :
2020-04-18
ISSN :
1527-1315
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background
CT and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT performances following immune therapy are not well known in patients with relapsed or refractory Hodgkin lymphoma (RRHL).
Purpose
To compare CT and ...
Lire la suite >Background CT and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT performances following immune therapy are not well known in patients with relapsed or refractory Hodgkin lymphoma (RRHL). Purpose To compare CT and PET/CT for prognostic value of early response evaluation following nivolumab therapy. Materials and Methods This retrospective study included patients from 34 institutions who underwent early imaging response evaluation from July 2013 to April 2017. Three experienced readers classified imaging response by using Cheson et al and 2016 Lymphoma Response to Immunomodulatory Therapy Criteria as follows: complete (metabolic) response, partial (metabolic) response, stable disease or no metabolic response, or progressive (metabolic) disease. Primary CT and PET assessments were performed at a median of 2.0 months (interquartile range, 1.7–3.7 months) after nivolumab initiation. Kaplan-Meier analysis was used to determine the relationship of primary CT and PET assessment response categories to overall survival (OS). Agreements between primary and secondary imaging assessments were assessed by using κ analysis. Results A total of 45 patients (median age, 37 years; range, 18–77 years; 25 men) underwent a primary assessment using CT and PET/CT; 36 patients also underwent a subsequent assessment. Eleven patients (24%) died after a median follow-up of 21.2 months. CT and PET response categories were associated with OS (P = .03 for primary CT assessment; P = .02 for primary PET assessment). There was no pseudoprogression at primary CT and PET assessments. At the primary assessment, response categories by using CT were reclassified by using PET in 44% (20 of 45) of patients. Among these, 55% (11 of 20) were reclassified to complete metabolic response (complete metabolic response rate: 29% [13 of 45 patients] vs complete response rate: 4% [two of 45 patients]), with a 2-year OS probability of 100%. At the secondary assessment, complete response rate using CT increased to 17% (six of 36 patients), hence a better agreement with PET (κ = 0.78; P < .001). Conclusion Early CT and PET/CT at a median of 2 months after initiation of nivolumab predicted overall survival in relapsed or refractory Hodgkin lymphoma. Early PET detected additional patients with complete metabolic response.Lire moins >
Lire la suite >Background CT and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT performances following immune therapy are not well known in patients with relapsed or refractory Hodgkin lymphoma (RRHL). Purpose To compare CT and PET/CT for prognostic value of early response evaluation following nivolumab therapy. Materials and Methods This retrospective study included patients from 34 institutions who underwent early imaging response evaluation from July 2013 to April 2017. Three experienced readers classified imaging response by using Cheson et al and 2016 Lymphoma Response to Immunomodulatory Therapy Criteria as follows: complete (metabolic) response, partial (metabolic) response, stable disease or no metabolic response, or progressive (metabolic) disease. Primary CT and PET assessments were performed at a median of 2.0 months (interquartile range, 1.7–3.7 months) after nivolumab initiation. Kaplan-Meier analysis was used to determine the relationship of primary CT and PET assessment response categories to overall survival (OS). Agreements between primary and secondary imaging assessments were assessed by using κ analysis. Results A total of 45 patients (median age, 37 years; range, 18–77 years; 25 men) underwent a primary assessment using CT and PET/CT; 36 patients also underwent a subsequent assessment. Eleven patients (24%) died after a median follow-up of 21.2 months. CT and PET response categories were associated with OS (P = .03 for primary CT assessment; P = .02 for primary PET assessment). There was no pseudoprogression at primary CT and PET assessments. At the primary assessment, response categories by using CT were reclassified by using PET in 44% (20 of 45) of patients. Among these, 55% (11 of 20) were reclassified to complete metabolic response (complete metabolic response rate: 29% [13 of 45 patients] vs complete response rate: 4% [two of 45 patients]), with a 2-year OS probability of 100%. At the secondary assessment, complete response rate using CT increased to 17% (six of 36 patients), hence a better agreement with PET (κ = 0.78; P < .001). Conclusion Early CT and PET/CT at a median of 2 months after initiation of nivolumab predicted overall survival in relapsed or refractory Hodgkin lymphoma. Early PET detected additional patients with complete metabolic response.Lire moins >
Langue :
Anglais
Audience :
Internationale
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Date de dépôt :
2023-05-25T03:37:03Z
2023-10-18T09:06:20Z
2023-10-18T09:06:20Z